Filing Flows › Medpace Holdings (MEDP) › Guidance & outlook
Medpace Holdings (MEDP) guidance and outlook
Medpace Holdings (MEDP) raised some and lowered other parts of its guidance on Oct 21, 2026: Revenue $2.8B–$2.9B for FY2026; Revenue +12% to +12.8% for FY2026; Net income $514M–$524M for FY2026; EPS $17.97–$18.32 for FY2026.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $2.8B–$2.9B | reaffirmed |
| Revenue | FY2026 | +12% to +12.8% | lowered |
| Net income | FY2026 | $514M–$524M | raised |
| EBITDA | FY2026 | $638M–$652M | new |
| EPS | FY2026 | $17.97–$18.32 | raised |
| Tax rate | FY2026 | 19%–19.5% | reaffirmed |
| EBITDA | FY2026 | $638M | raised |
From the earnings release filed Oct 21, 2026 (8-K on EDGAR).
Medpace Holdings' latest quarter
Medpace Holdings, Q3 2026: revenue $716M (+8% year over year), operating margin 23.1%, net earnings $137M, operating cash flow $217M. The chart follows the revenue to costs, profit and cash.
Questions
Did Medpace Holdings raise or lower its guidance?
Medpace Holdings (MEDP) raised some and lowered other parts of its guidance on Oct 21, 2026: Revenue $2.8B–$2.9B for FY2026; Revenue +12% to +12.8% for FY2026; Net income $514M–$524M for FY2026; EPS $17.97–$18.32 for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.